Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017

Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global PAD market. The report identifies the key trends shaping and driving the global PAD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PAD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The global PAD therapeutics market accounted for approximately $606m in 2009. In 2001, the market was valued at $405m and it grew at an approximate CAGR of 5.2% between 2001 and 2009. The global PAD therapeutics market is expected to reach $1 billion by 2017 growing at a CAGR of 6.5% between 2009 and 2017. The primary factor contributing to the increase in growth over the forecast period is the increase in disease incidence and the launch of new first-in-class drugs. Presently the therapeutic regimen for PAD consists of antiplatelet agents such as clopidogrel (Plavix) and ticlopidine (Ticlid). Blood thinners such as pentoxifyline (Trental) and Cilostazol (Pletal) are also prescribed. Like most cardiovascular complications, aspirin is used as a complementary drug in combination with the above mentioned drugs.

Scope

The report provides information on the key drivers and challenges of the PAD market. Its scope includes:

Annualized global PAD market revenues data from 2001 to 2009, forecast for eight years to 2017.

Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as of gene therapy, stem cell therapy, platelet aggregation inhibitor, Hydroxymethylglutaryl-CoA reductase inhibitor, monoclonal antibody, micro RNA, protein kinase modulator, Y2 agonist, and PPAR (Peroxisome Proliferator Activated Receptor) agonist.

Analysis of the current and future competition in the global PAD market. Key market players covered are Sanofi Aventis, Indigo pharmaceuticals, BioMarin Pharmaceutical, and AnGes MG Inc.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PAD therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global PAD market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global PAD market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next big thing in the global PAD market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 PAD THERAPEUTICS MARKET: INTRODUCTION

2.1 Overview
2.2 GlobalData Pipeline Report Guidance

3 PAD THERAPEUTICS MARKET: MARKET CHARACTERIZATION

3.1 PAD Therapeutics Market Size
3.2 PAD Therapeutics Market Forecast and CAGR
3.3 Drivers and Barriers for the PAD Therapeutics Market
  3.3.1 Drivers for the PAD Therapeutics Market
  3.3.2 Barriers for the PAD Therapeutics Market
3.4 Opportunity and Unmet Need
3.5 Key Takeaway

4 PAD THERAPEUTICS MARKET: COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Portfolio for Major Marketed Products in the PAD Therapeutics Market
  4.3.1 Plavix (Clopidogrel)
  4.3.2 Pletal (Cilostazol)
  4.3.3 Trental (pentoxifylline)
  4.3.4 Ticlid (ticlopidine)
4.4 Key Takeaway

5 PAD THERAPEUTICS MARKET: PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
  5.2.1 Technology Trends Analytical Framework
5.3 PAD Therapeutics – Promising Drugs under Clinical Development
5.4 Molecule Profiles for Promising Drugs Under Clinical Development
  5.4.1 Collategene
  5.4.2 NV1FGF
  5.4.3 INDI-702
5.5 PAD Therapeutics Market – Pipeline Assessment by Mechanism of Action
5.6 PAD Therapeutics Market – Pipeline Assessment by Clinical Phases of Development
  5.6.1 PAD Therapeutics – Phase III Clinical Pipeline
  5.6.2 PAD Therapeutics – Phase II Clinical Pipeline
  5.6.3 PAD Therapeutics – Phase I Clinical Pipeline
  5.6.4 PAD Therapeutics – Preclinical Pipeline
  5.6.5 PAD Therapeutics – Discovery Clinical Pipeline
5.7 Key Takeaway

6 PAD THERAPEUTICS MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

7 PAD THERAPEUTICS MARKET: KEY PLAYERS IN THE PAD THERAPEUTICS MARKET

7.1 Sanofi-Aventis
  7.1.1 Overview
  7.1.2 Financial Performance
  7.1.3 Business Description
  7.1.4 Cardiovascular Pipeline Portfolio
  7.1.5 PAD Pipeline Portfolio
7.2 Indigo Pharmaceuticals
  7.2.1 Overview
  7.2.2 PAD Pipeline Portfolio
7.3 BioMarin Pharmaceutical
  7.3.1 Overview
  7.3.2 Financial Performance
  7.3.3 Business Description
  7.3.4 PAD Pipeline Portfolio
7.4 AnGes MG, Inc.
  7.4.1 Overview
  7.4.2 Financial Performance
  7.4.3 Business Description

8 PAD THERAPEUTICS MARKET: APPENDIX

8.1 Definitions
8.2 Scope of Pipeline Research
8.3 Acronyms
8.4 Research Methodology
  8.4.1 Coverage
  8.4.2 Secondary Research
  8.4.3 Forecasting
  8.4.4 Primary Research
  8.4.5 Expert Panel Validation
8.5 Contact Us
8.6 Disclaimer
8.7 Sources 39

LIST OF TABLES


Table 1: Ankle-Brachial Index and Severity of Peripheral Arterial Disease
Table 2: PAD Therapeutics Market, Global, Revenue ($m), 2001–2009
Table 3: PAD Market, Global, Market Forecasts ($m), 2009–2017
Table 4: Comparison of Major Marketed Products for PAD, 2010
Table 5: PAD Therapeutics Market, Global, Most Promising Molecules under Clinical Development, 2010
Table 6: PAD Therapeutics – Filed, Phase IV and Phase III Pipeline Products, 2010
Table 7: PAD Therapeutics – Phase II Clinical Pipeline, 2010
Table 8: PAD Therapeutics – Phase I Clinical Pipeline, 2010
Table 9: PAD Therapeutics – Preclinical Pipeline, 2010
Table 10: PAD Therapeutics – Discovery Pipeline, 2010
Table 11: Cardiovascular Pipeline Portfolio – Sanofi-Aventis, 2010
Table 12: Sanofi-Aventis – PAD Pipeline Portfolio, 2010
Table 13: Indigo Pharmaceuticals - PAD Pipeline Portfolio, 2010
Table 14: BioMarin Pharmaceuticals - PAD Pipeline Portfolio, 2010
Table 15: AnGes MG Pharmaceuticals - PAD Pipeline Portfolio, 2010 32

LIST OF FIGURES

Figure 1: PAD Therapeutics Market, Global, Revenues ($m), 2001-2009
Figure 2: PAD Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2017
Figure 3: Opportunity and Unmet Need in the PAD Therapeutics Market, 2010
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for PAD , 2010
Figure 5: Technology Trends Analytic Framework of the PAD Therapeutics Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the PAD Therapeutics Pipeline – Description, 2010
Figure 7: PAD Therapeutics – Clinical Pipeline by Mechanism of Action, 2010
Figure 8: PAD Therapeutics – Pipeline by Phase of Clinical Development, 2010
Figure 9: PAD Therapeutics Market, Global, Implications for Future Market Competition in the PAD Therapeutics Market, 2010
Figure 10: PAD Therapeutics – Clinical Pipeline by Company, 2010
Figure 11: GlobalData Market Forecasting Model, 2010 37

COMPANIES MENTIONED

Sanofi-Aventis
Indigo Pharmaceuticals
BioMarin Pharmaceutical
AnGes MG, Inc. Skip to top